Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
March 09, 2023 10:02 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Participation in Upcoming Conferences
March 01, 2023 16:44 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
December 02, 2022 17:02 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference
November 23, 2022 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results
November 10, 2022 16:15 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 04, 2022 11:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Participation in Four Upcoming Conferences
August 31, 2022 16:52 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results
August 11, 2022 16:10 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs
June 06, 2022 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, June 06, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Present at Upcoming Investor Conferences
May 17, 2022 16:05 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...